The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have …

Bladder CancerSquamous Cell Carcinoma of the LungEsophageal Squamous Cell Carcinoma+8 more

~Estimated

~$10 – $8,750

EvolveImmune United, IncNCT07217171

Phase 1

First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this…

Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Anal CanalColorectal Cancer+8 more

~Estimated

~$10 – $8,750

Bicara TherapeuticsNCT04429542